At Boreal, we are committed to improving cancer patient care through development of technologies for blood-based detection and monitoring of circulating tumor DNA.

Today, genomic profiling of cancer is increasingly important for cancer research, clinical trials and drug development programs. As more targeted therapies are developed and approved, recurrent genomic profiling of tumors will be essential for administration of therapy, patient selection in clinical trials, and monitoring of therapy response. New approaches are required as current technologies for tumor mutation detection are invasive and not well suited for repeated tumor profiling. We are overcoming this challenge by developing breakthrough technology for non-invasive, real-time detection and monitoring of tumor mutations.

We are a team of specialists in molecular biology, engineering and physics with a passion to develop technology that impacts cancer research and treatment. We are confident that our technology will enable the first practical method for non-invasive tumor profiling. We invite you to join us in our quest to help cancer researchers and clinicians transform patient care through earlier detection and monitoring of cancer.